A Lancet Neurology study measuring 130 blood proteins across 2,385 samples from patients receiving lecanemab found that the markers tracking amyloid clearance were largely distinct from those tracking later cognitive decline. Brain-derived tau variants outperformed peripherally produced forms in distinguishing treated patients from untreated controls. The findings point toward multi-marker blood profiling as a route to understanding why identical diagnoses and identical therapies produce divergent outcomes.
Key Points
- Amyloid clearance markers differ from markers predicting later cognitive decline
- 34 of 130 proteins shifted significantly with lecanemab infusion count
- Brain-derived tau outperformed peripheral tau in separating treated from untreated
Longevity Analysis
Removing a pathological protein and preserving cognitive function appear to run on separate biological tracks, which reframes amyloid clearance as one input among several rather than the endpoint itself. Inflammation, neuronal injury and synaptic integrity markers moving in different directions within the same treated patients argue for reading neurodegeneration as a multi-system process involving defense, clearance and regenerative capacity in the brain. For clinicians, the practical value lies in interpreting a panel of signals over time rather than anchoring decisions to a single number — though whether any of these markers predicts response before treatment begins remains unanswered.
Original published by Longevity.Technology, by Kyle Umipig.